Evidence map›Paper›PMID 18765688›Full record

ArticleAntimicrobial agents and chemotherapy2008

Prevalence and mechanisms of broad-spectrum beta-lactam resistance in Enterobacteriaceae: a children's hospital experience.

Xuan Qin, Danielle M Zerr, Scott J Weissman, Janet A Englund, Donna M Denno, Eileen J Klein, Phillip I Tarr, Justin Kwong, Jennifer R Stapp, Luis G Tulloch and 1 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. ESBL and AmpC β-Lactamases in Clinical Strains ofMedicina (Kaunas, Lithuania) · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Detection and genotype analysis of AmpC β-lactamase inExperimental and therapeutic medicine · 2016
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xuan QinDepartment of Laboratory Medicine, Microbiology Laboratory, Children's Hospital and Regional Medical Center, NE, Seattle, WA 98105-0371, USA. xuan.qin@seattlechildrens.org
Danielle M Zerr
Scott J Weissman
Janet A Englund
Donna M Denno
Eileen J Klein
Phillip I Tarr
Justin Kwong
Jennifer R Stapp
Luis G Tulloch
Emmanouil Galanakis
University of Washington · USSeattle Children's Hospital · USWashington University in St. Louis · US

Funding

Washington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2000 to 2026
$30.8M
NIDDK NIH HHS 5P30 DK052574
6 · The paper itself

Abstract

The objective of this study was to investigate the trends and patterns of resistance in beta-lactamase-producing members of the family Enterobacteriaceae in a children's hospital over a 9-year period (1999 to 2007). Clinically significant isolates of the Enterobacteriaceae were screened for patterns of broad-spectrum resistance to beta-lactams. The strains likely to be resistant were subsequently confirmed by an inhibitor-based disc test. The plasmid-mediated resistance determinants in these isolates were identified by PCR and by in vitro transformation, which successfully reproduced the AmpC phenotype unrestricted by the species of the host organisms. Among 8,048 Enterobacteriaceae isolates belonging to the four chromosomal ampC-negative or -nonfunctional genera, 86 (1.07%) isolates (56 Escherichia coli isolates, 22 Klebsiella species isolates, 1 Proteus mirabilis isolate, and 7 Salmonella species isolates) exhibited broad-spectrum beta-lactam resistance patterns. These organisms collectively produced three classes of beta-lactamases, including class A extended-spectrum beta-lactamases (n = 47), class C or AmpC beta-lactamases (n = 36, including 4 isolates that produced both class A and class C enzymes), and class A or B carbapenem-hydrolyzing beta-lactamases (n = 3). The proportion increased from 0.46% during the first 3 years to 1.84% during the last 3 years (relative risk [RR], 4.04; 95% confidence interval [CI], 2.28 to 7.42; P < 0.001). The increase was mainly due to the emergence of a plasmid-mediated bla(CMY-2) beta-lactamase, the incidence of which increased from 0.11% during the first 3 years to 0.96% during the last 3 years (RR, 9.11; 95% CI, 2.76 to 30.1; P = 0.001). Class A-type resistance increased slightly during the study period, from 0.35% during the first 3 years to 0.85% during the last 3 years (RR, 2.42; 95% CI, 1.15 to 5.07; P = 0.02). A Proteus mirabilis strain was documented to possess a novel bla(DHA) determinant. Of special concern, three carbapenemase-producing isolates were identified between 2003 and 2006. The infections caused by resistant isolates of the Enterobacteriaceae mainly affected hospitalized patients with underlying conditions; however, 19 (22%) episodes were of community onset in otherwise well children. The rate of resistance to broad-spectrum beta-lactams among isolates of the Enterobacteriaceae is increasing in children in both hospital- and community-acquired settings, and the resistance is driven largely by plasmid-mediated AmpC beta-lactamases. These data have important implications for empirical antimicrobial strategies targeting serious pediatric infections. Further study of this problem is warranted.

Indexed as

beta-Lactam ResistanceAdolescentAdultBase Sequencebeta-LactamasesChildChild, PreschoolCommunity-Acquired InfectionsDNA, BacterialDNA PrimersEnterobacteriaceaeEnterobacteriaceae InfectionsFemaleGenes, BacterialHospitals, PediatricHumansbeta-LactamasesDNA, BacterialDNA Primers

Identifiers

PMID18765688
PMCPMC2573145
OpenAlexW2138321091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.